Clinical trials: Shingles
Varicella
Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
This study is conducted in order to collect clinical samples from patients who are diagnosed of having chickenpox infection. The results of this study will provide basic scientific information about chickenpox disease.
- Trial name
- NCT00127608
- Testing
- Collection of clinical samples
- Where
- Czechia
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, HIV Infections
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV.
- Trial name
- NCT00851786
- Testing
- ZOSTAVAX
- Where
- 43 sites in United States
- Volunteers
- 395 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
- Trial name
- NCT00550745
- Testing
- Zoster Vaccine, Live
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem…
- Trial name
- NCT00920218
- Testing
- Herpes Zoster Vaccine 1437173A
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Shingles
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
- Trial name
- NCT01505647
- Testing
- Zoster Vaccine, Live (AMP), Zoster Vaccine, Live
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neuralgia,Postherpetic
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control.
- Trial name
- NCT00636636
- Testing
- Gabapentin Extended Release tablets
- Where
- 39 sites in United States, Argentina and 1 more
- Volunteers
- 452 people
- Sponsor
- Depomed
Herpes Zoster
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile to that of…
- Trial name
- NCT00130793
- Testing
- Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation, Comparator: zoster vaccine live (Oka/Merck) frozen formulation
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age…
- Trial name
- NCT02690207
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 195 sites in United States, Australia and 16 more
- Volunteers
- 8,687 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella, Chickenpox Vaccines
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in the prevention of varicella disease in…
- Trial name
- NCT00226499
- Testing
- Priorix-tetra™, Priorix™, Varilrix™
- Where
- 104 sites in Czechia, Greece and 8 more
- Volunteers
- 5,803 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pain, Quality of Life
Simultaneous RZV and aIIV4 Vaccination
The overall aim of the study is to compare the safety of simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®) versus simultaneous Zoster Vaccine…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Trial name
- NCT05007041
- Testing
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Where
- 2 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Duke University
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster Keratitis
Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis
The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis.
- Trial name
- NCT02382588
- Testing
- gancyclovir gel, Hypromellose gel
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hepatitis C
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
This study aims to identify the innate and adaptive immune response to zoster vaccination. Half of the participants will be individuals with chronic hepatitis C, while the other half with healthy volunteers.The innate immune…
- Trial name
- NCT02590068
- Testing
- Zoster vaccine live
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Herpes Zoster
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
A study in two parts (Part A and Part B) to evaluate the responsiveness of various biomarkers of immunity to Varicella-Zoster Virus (VZV) following repeated immunizations with heat treated VZV vaccine V212 or with Zostavax™.
- Trial name
- NCT00886613
- Testing
- V212, Comparator: Zostavax™, VZV Skin Test
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia
Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve
Herpes zoster (commonly referred to as "shingles") results from the reactivation of the varicella-zoster virus acquired during a primary infection, usually chickenpox.
- Trial name
- NCT01886313
- Testing
- Civamide Nasal Spray
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Winston Laboratories
Herpes Zoster
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT02052596
- Testing
- Herpes Zoster vaccine GSK 1437173A, Boostrix
- Where
- 13 sites in United States
- Volunteers
- 935 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Shingles
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01331161
- Testing
- ZOSTAVAX
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Emory University
Herpes Zoster Disease
Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Despite the significant benefits of herpes zoster vaccine (HZV), vaccination rates remain low. Electronic medical records (EMR) can serve as a practical strategy to better facilitate the application of preventative health care…
- Trial name
- NCT01519570
- Testing
- An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
- Where
- United States
- Volunteers
- 2,589 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Hepatitis A, Measles
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly.
- Conditions
- Hepatitis A, Measles, Mumps, Rubella
- Trial name
- NCT00326183
- Testing
- VAQTA®, ProQuad
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC